Separate coverage said the FDA has set a review date and an advisory committee timeline for uniQure’s Huntington’s disease gene therapy, with a decision targeted for May 1. The report also flagged concurrent market moves tied to other gene therapy and biotech news, underscoring how regulatory milestones can quickly reshape expectations. For investors, the key near-term catalyst is the agency’s determination on approval and whether the agency will bring the data to an adcomm forum. The timeline matters for clinical-stage and platform-based gene therapy developers watching for precedent on evidentiary standards. The update reinforces uniQure’s move into the final stretch of FDA review after BLA acceptance and Priority Review classification.